Curtin, Nicola J. http://orcid.org/0000-0003-1369-1843
Drew, Yvette http://orcid.org/0000-0001-6676-9224
Sharma-Saha, Sweta
Article History
First Online: 3 October 2019
Competing interests
: N.J.C. has received research funding from Aguoron Pharmaceuticals and Pfizer for the development of rucaparib, from BioMarin for studies of talazoparib and from Tesaro for studies of niraparib. N.J.C. has also been paid by Abbvie for consultancy relating to the development of veliparib. N.J.C. is an inventor on the patent relating to the use of rucaparib in homologous recombination repair-deficient cancer, and Newcastle University receives royalty income from the sales of rucaparib that are shared with contributors to its development, including N.J.C. and Y.D. Y.D. has received research grant funding from AstraZeneca, Clovis Oncology and Tesaro and has participated in scientific advisory boards for AstraZeneca, Clovis Oncology, Merck and Tesaro. Y.D. is also a principal investigator of clinical trials of olaparib and rucaparib. S.S.-S. declares no competing interests.